coronavirus
belong
group
envelop
positivesingl
strand
rna
virus
known
caus
sever
respiratori
distress
anim
human
current
sar
sar
pandem
caus
infect
global
nearli
death
coronavirus
enter
suscept
cell
via
fusion
viral
envelop
plasma
membran
andor
via
fusion
viral
envelop
endosom
membran
endocytosi
viru
endosom
previou
result
sar
mer
cov
shown
spike
glycoprotein
major
determin
viru
infect
immunogen
herein
show
express
sar
sn
glycoprotein
transient
transfect
african
green
monkey
kidney
vero
cell
caus
extens
cell
fusion
comparison
limit
cell
fusion
caus
sar
glycoprotein
sn
express
detect
intracellularli
transfect
vero
cell
surfac
caus
format
larg
multinucl
cell
syncytia
hour
post
transfect
result
agreement
publish
patholog
observ
extens
syncyti
format
lung
tissu
patient
differenti
sn
versu
somedi
cell
fusion
suggest
abl
spread
celltocel
much
effici
sar
effect
avoid
extracellular
space
neutral
antibodi
systemat
screen
sever
drug
abil
inhibit
sn
cell
fusion
reveal
fda
approv
hivproteas
inhibitor
nelfinavir
mesyl
viracept
drastic
inhibit
sn
somedi
cell
fusion
dosedepend
manner
complet
inhibit
cell
fusion
observ
micromolar
concentr
comput
model
silico
dock
experi
suggest
possibl
nelfinavir
may
bind
insid
trimer
structur
proxim
amino
terminu
directli
inhibit
sn
somedi
membran
fusion
also
possibl
nelfinavir
mesyl
act
cellular
process
inhibit
proteolyt
process
result
warrant
investig
potenti
nelfinavir
mesyl
antivir
drug
especi
earli
time
symptom
appear
sever
acut
respiratori
syndrom
coronaviru
current
associ
global
pandem
caus
coronaviru
diseas
first
note
decemb
wuhan
provinc
china
result
diseas
term
coronaviru
character
acut
respiratori
diseas
pneumonia
infect
nearli
million
peopl
caus
nearli
death
worldwid
predilect
older
peopl
andor
peopl
health
issu
includ
hypertens
diabet
obes
comorbid
sar
third
human
coronavirus
appear
first
time
centuri
one
two
coronavirus
sar
appear
novemb
china
caus
infect
worldwid
death
sar
effect
contain
appar
viru
although
caus
high
degre
mortal
infect
individu
effect
transmit
one
persontoth
second
human
coronaviru
middl
east
respiratori
syndrom
coronaviru
merscov
appear
caus
limit
epidem
thousand
peopl
high
death
rate
approxim
predominantli
middl
east
saudi
arabia
primari
sourc
infect
found
dromedari
camel
although
viru
transmit
person
person
close
proxim
hospit
set
coronavirus
specifi
spike
glycoprotein
embed
viral
envelop
trimer
form
give
characterist
corona
structur
glycoprotein
major
antigen
respons
receptor
bind
membran
fusion
properti
identifi
cell
receptor
sar
also
sar
unknown
human
receptor
may
respons
wider
infecti
spread
sar
spike
cleav
two
major
compon
via
cellular
proteas
viru
entri
cell
mediat
bind
receptorbind
domain
rbd
locat
ectodomain
cleavag
glycoprotein
produc
protein
mediat
cellular
proteas
junction
well
site
locat
near
proteolyt
cleavag
fusion
viral
envelop
cellular
membran
mediat
protein
contain
put
fusion
peptid
region
mechan
membran
pore
format
lead
membran
fusion
involv
format
sixhelix
bundl
fusion
core
two
heptad
repeat
domain
found
monom
form
initi
pore
result
membran
fusion
cellular
serin
proteas
implic
prime
cleavag
well
cleavag
requir
initi
membran
fusion
event
also
sarss
cleav
cellular
proteas
cathepsin
l
low
ph
endosom
therebi
expos
domain
spike
protein
membran
fusion
cellsurfac
express
mediat
sinduc
cell
fusion
format
syncytia
phenomenon
similar
viru
entri
requir
presenc
virusinduc
cell
fusion
mechan
viru
spread
celltocel
phindepend
mechan
avoid
extracellular
space
potenti
evad
neutral
antibodi
demonstr
rbd
domain
sar
sn
higher
bind
affin
receptor
sar
protein
two
virus
nearli
ident
nelfinavir
mesyl
develop
antihiv
proteas
inhibitor
addit
potent
activ
hiv
proteas
nelfinavir
mesyl
found
produc
multipl
effect
cellular
process
includ
induct
apoptosi
necrosi
well
induct
cell
protect
mechan
includ
cell
cycl
retard
unfold
protein
respons
nelfinavir
mesyl
effect
exploit
anticanc
purpos
previous
shown
nelfinavir
mesyl
inhibit
sar
cov
replic
cell
cultur
previous
investig
structur
function
sar
glycoprotein
transient
transfectionmembran
fusion
assay
base
initi
studi
undertook
screen
number
compound
may
inhibit
smediat
fusion
transient
express
african
green
monkey
kidney
cell
vero
report
herein
sar
sn
caus
extrem
smediat
membran
fusion
comparison
cell
fusion
caus
transient
express
importantli
report
nelfinavir
mesyl
inhibit
smediat
fusion
micromolar
rang
silico
dock
experi
reveal
possibl
nelfinavir
bind
amino
terminu
within
trimer
thu
may
direct
inhibit
format
heptadrepeat
complex
caus
smediat
membran
fusion
base
result
research
nelfinavir
effect
human
patient
warrant
cell
line
african
green
monkey
kidney
vero
cell
maintain
dulbeco
modifi
eagl
media
dmem
fetal
bovin
serum
fb
primocin
invitrogen
inc
ca
usa
nelfinavir
mesyl
dmso
bought
sigma
inc
mo
usa
primari
antibodi
use
follow
mous
antimyc
antibodi
abcam
usa
mous
antiflag
antibodi
abcam
usa
goat
antimous
antibodi
conjug
hrp
invitrogen
inc
ca
usa
use
secondari
antibodi
vector
nova
red
peroxidas
hrp
substrat
kit
vector
laboratori
ca
usa
use
imag
goat
antimous
antibodi
conjug
alexa
fluorophor
goat
antirabbit
antibodi
conjug
alexa
fluor
invitrogen
inc
ca
usa
use
immunofluoresc
ifa
assay
construct
recombin
spike
protein
sar
sn
spike
express
plasmid
use
present
studi
construct
similar
manner
gene
place
control
human
cytomegaloviru
immedi
earli
cmv
promot
engin
contain
nmyc
epitop
tag
amino
termin
end
respect
sn
clone
sigma
sino
biolog
parent
vector
plasmid
respect
subunit
sn
express
construct
contain
amino
terminu
aa
gli
n
termin
domain
sn
subunit
engin
exactli
contain
nmyc
tag
amino
terminu
encompass
sn
amino
acid
sequenc
transient
transfect
assay
vero
cell
grown
well
plate
transient
transfect
either
sn
use
lipofectamin
reagent
approxim
lipofectamin
microgram
plasmid
dna
use
transfect
per
well
vero
cell
appropri
control
also
use
follow
hour
plate
examin
phase
contrast
microscopi
fuse
cell
imag
taken
live
condit
well
either
formalin
methanol
fixat
cell
stain
flag
nmyc
sn
hrp
vector
nova
red
kit
phase
contrast
microscopi
similarli
cell
stain
fluoresc
microscopi
use
antimous
antibodi
conjug
alexa
fluorophor
antirabbit
antibodi
conjug
alexa
fluorophor
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
inhibit
smediat
cell
fusion
nelfinavir
nelfinavir
mesyl
dissolv
dmso
concentr
stock
seri
dilut
made
serum
free
dmem
follow
transfect
microlit
nelfinavir
mesyl
solut
ad
well
vero
cell
transfect
either
sn
incub
drug
hour
tissu
cultur
plate
observ
fuse
cell
phase
contrast
fluoresc
imag
taken
either
formalin
methanol
fix
condit
comput
method
dock
nelfinavir
mesyl
spike
protein
sar
perform
use
autodock
crystal
structur
nelfinavir
obtain
complex
hivproteas
nelfinavir
crystal
structur
protein
data
bank
pdb
id
structur
prefus
protein
report
wrapp
et
al
pdb
id
trimer
structur
spike
protein
use
dock
protein
structur
spike
protein
exist
dynam
condit
bind
receptor
fusion
host
cell
grid
dock
creat
spike
protein
structur
particular
dock
site
center
cover
grid
box
x
z
direct
center
grid
one
grid
site
creat
around
proteas
cleavag
site
anoth
cover
region
protein
trimer
figur
support
inform
dock
calcul
perform
use
lamarckian
genet
algorithm
start
conform
million
energi
evalu
fifti
low
energi
dock
structur
use
final
analysi
structur
within
kcalmol
lowest
energi
dock
structur
repres
final
possibl
dock
structur
use
pymol
softwar
schroding
instrument
softwar
olympu
fluoresc
microscop
use
live
phase
contrast
imag
use
cellsen
softwar
zeiss
axio
observ
fluoresc
microscop
use
fluoresc
imag
use
zen
softwar
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
viru
entri
achiev
smediat
fusion
viral
envelop
either
cellular
plasma
membran
endosom
membran
smediat
cell
fusion
caus
cellsurfac
express
thought
surrog
model
viru
entri
cell
fusion
previous
report
detail
analysi
function
domain
sar
spike
glycoprotein
import
smediat
membran
fusion
format
multinucl
cell
syncytia
includ
delin
domain
import
synthesi
cellsurfac
express
endocytosi
cell
surfac
compar
somedi
fusion
versu
sn
gene
clone
transient
express
vector
codonoptim
gene
carri
nmyc
epitop
tag
amino
termini
fig
b
e
f
addit
domain
sn
clone
independ
transient
express
vector
encompass
amino
acid
domain
domain
express
myc
epitop
tag
amino
termini
fig
c
vero
cell
transfect
sn
express
plasmid
detect
hour
post
transfect
hpt
use
antimyc
antiflag
antibodi
conjunct
secondari
antibodi
link
horseradish
peroxidas
see
materi
method
vero
cell
also
transfect
plasmid
vehicl
control
mocktransfect
express
sn
readili
detect
immunohistochemistri
signal
obtain
vero
mocktransfect
hrpstain
control
cell
monolay
phase
contrast
microscopi
reveal
presenc
extens
syncyti
format
sn
transfect
cell
remain
monolay
appear
exhibit
cellular
toxic
fig
examin
transfect
vero
cell
immunofluoresc
stain
cellular
tubulin
antialpha
tubulin
antibodi
nuclei
dapi
anti
nmyc
antiflag
antibodi
follow
antimous
fluoresc
antibodi
provid
addit
support
untransfect
monolay
appear
normal
sn
express
produc
larg
syncytia
contrast
much
smaller
syncytia
form
transient
express
fig
express
either
domain
sn
readili
detect
immunohistochemistri
antinmyc
antibodi
howev
substanti
cell
fusion
observ
hpt
fig
well
later
time
shown
transient
transfect
vero
cell
treat
either
dmso
seri
dilut
nelfinavir
mesyl
follow
hour
post
transfect
cell
fix
methanol
stain
either
nmyc
sn
flag
nelfinavir
mesyl
treatment
inhibit
overal
sn
express
evidenc
effici
express
detect
protein
via
immunohistochemistri
sn
mediat
fusion
significantli
inhibit
nelfinavir
dose
depend
manner
complet
inhibit
observ
lowest
effect
concentr
micromolar
compar
untreat
control
fig
b
determin
effect
nelfinavir
surfac
express
spike
transient
transfect
vero
cell
plasmid
express
either
sn
glycoprotein
tag
nmyc
epitop
amino
termini
respect
treat
cell
either
nelfinavir
dmso
hour
cell
observ
characterist
syncytia
format
fix
either
formalin
methanol
detect
surfac
express
endogen
express
spike
glycoprotein
follow
nelfinavir
treatment
although
signific
differ
number
fuse
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
cell
size
syncytia
follow
drug
treatment
appar
differ
visibl
surfac
express
spike
compar
total
spike
express
sn
sotransfect
cell
experi
reveal
nelfinavir
concentr
significantli
inhibit
cell
fusion
affect
sn
cell
surfac
express
fig
comput
model
nelfinavirsn
potenti
interact
silico
dock
experi
perform
investig
whether
nelfinavir
potenti
directli
bind
sn
glycoprotein
two
dock
grid
creat
specif
encompass
cleavag
site
nearbi
area
region
trimer
form
sn
fig
dock
grid
creat
cover
cleavag
site
low
energi
dock
structur
nelfinavir
bound
pocket
helic
fusion
peptid
region
lower
part
ntd
region
fig
dock
energi
nelfinavir
bound
structur
kcalmol
lowest
energi
dock
conform
complex
stabil
three
hydrogen
bond
hydrophob
interact
protein
fusion
peptid
form
two
hydrogen
bond
helix
form
one
hydrogen
bond
nelfinavir
hydrophob
interact
domin
aromat
function
group
nelfinavir
side
chain
alkyl
group
protein
fig
dock
grid
around
helic
trimer
lowest
energi
dock
structur
bound
near
helic
region
dock
energi
kcalmol
dock
complex
stabil
three
hydrogen
bond
protein
nelfinavir
form
hydrogen
bind
interact
nelfinavir
wherea
form
hydrophob
interact
fig
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
virus
membran
fusion
phenomena
caus
express
fusogen
glycoprotein
infect
cell
surfac
celltocel
fusion
mediat
viral
glycoprotein
similar
fusion
viral
envelop
cellular
membran
typic
occur
plasma
membran
physiolog
ph
endocytosi
virion
envelop
particl
within
endosom
follow
fusion
viral
envelop
endosom
membran
releas
nucleocapsid
protein
cytoplasm
virusinduc
cell
fusion
import
cytopath
phenomenon
viru
spread
celltocel
avoid
extracellular
space
exposur
neutral
antibodi
virusinduc
cell
fusion
also
caus
hyperinflammatori
respons
produc
advers
effect
infect
host
herein
show
sar
spike
sn
glycoprotein
caus
significantli
cell
fusion
syncytia
format
comparison
sar
spike
glycoprotein
follow
transient
express
vero
cell
importantli
show
nelfinavir
mesyl
current
prescrib
antihiv
proteas
inhibitor
drastic
inhibit
sn
somedi
cell
fusion
result
indic
highli
like
increas
sar
virul
sar
may
attribut
enhanc
fusogen
exhibit
sn
comparison
glycoprotein
importantli
fact
nelfinavir
significantli
inhibit
sn
somedi
cell
fusion
suggest
test
antivir
especi
earli
time
first
symptom
exhibit
infect
individu
transient
express
sn
glycoprotein
produc
drastic
differ
cell
fusion
overal
protein
express
similar
evidenc
immunohistochemistri
signal
obtain
hpt
enhanc
fusogen
sar
versu
sar
recent
note
infect
vero
cell
valid
transient
transfect
result
reflect
spikemedi
virusinduc
cell
fusion
differ
sar
sar
cellsurfac
express
sn
compar
suggest
observ
differ
membran
fusion
due
inher
differ
structur
function
sn
versu
glycoprotein
interestingli
independ
express
sn
domain
caus
cell
fusion
clear
whether
two
domain
could
process
express
cellsurfac
although
domain
could
detect
via
immunohistochemistri
shown
result
suggest
entir
glycoprotein
need
express
uncleav
form
may
proteolyt
process
either
within
endosom
cell
surfac
proteas
known
requir
spike
activ
viru
entri
util
sn
transient
express
system
screen
current
avail
drug
may
inhibit
smediat
cell
fusion
format
syncytia
found
nelfinavir
mesyl
known
current
prescrib
antihiv
drug
significantli
inhibit
sn
somedi
cell
fusion
micromolar
concentr
result
signific
nelfinavir
appear
inhibit
overal
sn
synthesi
cellsurfac
express
comput
model
reveal
nelfinavir
may
directli
bind
trimer
form
sn
near
put
fusogen
domain
thu
may
directli
inhibit
smediat
cell
fusion
howev
nelfinavir
pleotrop
effect
multipl
cellular
process
includ
induc
apoptosi
er
stress
certain
condit
investig
anticanc
purpos
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
thu
possibl
cellular
signal
process
affect
alter
posttransl
process
sn
without
affect
cellsurfac
express
also
possibl
nelfinavir
may
inhibit
cellular
proteas
includ
may
requir
sn
fusion
activ
preliminari
experi
indic
sn
may
cleav
vero
cell
presenc
nelfinavir
although
current
known
whether
cleavag
occur
effici
addit
transfect
cell
express
sn
presenc
nelfinavir
appear
exhibit
morpholog
indic
cellular
cytotox
suggest
nelfinavir
cytotox
concentr
use
studi
overal
experi
suggest
nelfinavir
use
combat
infect
earli
first
symptom
exhibit
infect
patient
minim
viru
spread
provid
suffici
time
infect
patient
mount
protect
immun
respons
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
figur
schemat
spike
glycoprotein
recombin
gene
construct
structur
spike
aa
glycoprotein
show
domain
cleavag
site
b
structur
sn
spike
clone
kpnl
xbal
restrict
site
ntermin
amino
acid
replac
signal
peptid
sp
nmyc
sequenc
c
structur
domain
also
clone
kpnl
xbal
restrict
site
ntermin
amino
acid
replac
signal
peptid
sp
nmyc
sequenc
structur
domain
clone
kpnl
xbal
restrict
site
ntermin
contain
signal
peptid
sp
nmyc
sequenc
e
structur
sar
spike
glycoprotein
show
domain
cleavag
site
structur
sar
spike
express
plasmid
construct
describ
previous
similar
except
flag
instead
nmyc
use
detect
heptad
repeat
heptad
repeat
ntd
non
translat
domain
rbd
receptor
bind
domain
fp
fusion
peptid
sp
sar
signal
peptid
sp
signal
peptid
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
cellular
tubulin
stain
rabbit
antialpha
tubulin
abcam
antirabbit
secondari
antibodi
conjug
alexa
fluor
dapi
use
stain
nuclei
cell
phase
contrast
imag
taken
magnif
wherea
fluoresc
imag
taken
magnif
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
figur
express
sar
spike
domain
vero
cell
transfect
plasmid
express
either
domain
tag
nmyc
epitop
amino
termini
express
detect
mab
epitop
tag
hour
post
transfect
compar
vehicl
contain
equival
amount
lipofectamin
methanol
fix
cell
incub
mous
antimyc
antibodi
stain
hrp
stain
follow
goat
antimous
secondari
antibodi
incub
imag
taken
magnif
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
antinmyc
sn
mous
antiflag
antibodi
stain
hrp
stain
follow
goat
antimous
secondari
antibodi
incub
imag
taken
magnif
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
figur
propos
model
cov
protein
interact
base
dock
dock
near
site
result
dock
nelfinavir
bind
fusion
peptid
fp
yellow
helic
region
heptad
region
cyan
helix
nelfinavir
shown
red
stick
amino
acid
protein
form
interact
nelfinavir
shown
stick
singl
letter
code
amino
acid
b
dock
nelfinavir
region
nelfinavir
shown
blue
stick
sake
clariti
amino
acid
protein
form
interact
nelfinavir
shown
blue
stick
singl
letter
code
amino
acid
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
